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Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical
practice due to their anxiolytic, hypnotic, and muscle relaxant properties. Yet,
their chronic use is associated with cases of abuse, dependence, and relapse
in many patients. Furthermore, elderly people are susceptible to alterations in
pharmacodynamics, pharmacokinetics as well as to drug interaction due to
polypharmacy. These situations increase the risk for the appearance of cognitive
affectations and the development of pathologies like Alzheimer’s disease (AD). In the
present work, there is a summary of some clinical studies that have evaluated the effect
of BZDs and Z-drugs in the adult population with and without AD, focusing on the
relationship between their use and the loss of cognitive function. Additionally, there is an
assessment of preclinical studies focused on finding molecular proof on the pathways
by which these drugs could be involved in AD pathogenesis. Moreover, available data
(1990–2019) on BZD and Z-drug use among elderly patients, with and without AD, was
compiled in this work. Finally, the relationship between the use of BZD and Z-drugs for
the treatment of insomnia and the appearance of AD biomarkers was analyzed. Results
pointed to a vicious circle that would worsen the condition of patients over time. Likewise,
it put into relevance the need for close monitoring of those patients using BZDs that
also suffer from AD. Consequently, future studies should focus on optimizing strategies
for insomnia treatment in the elderly by using other substances like melatonin agonists,
which is described to have a much more significant safety profile.
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INTRODUCTION
Sleep disturbances have been reported to increase Amyloid
Beta (Aβ) levels in the cerebrospinal fluid of healthy subjects,
contributing to the advancement of neurodegeneration and the
appearance of mild cognitive impairment (MCI) (Lopez et al.,
1999; Virta et al., 2007; Modabbernia et al., 2011; Consensus
and Statements, 2014; Di Meco et al., 2014; Benedict et al.,
2015; Gage et al., 2015; Chen et al., 2016; Gaugler et al., 2016;
Kincheski et al., 2017; La Frenais et al., 2017; Livingston et al.,
2017; Atkin et al., 2018; Burke et al., 2018). At preclinical
level, it has been described that sleep deprivation in 3xTg
mice acts as a chronic stressor, favoring the decrease of Cyclic
adenosine monophosphate (cAMP) response element binding
(CREB) and affecting synaptic plasticity and cognitive functions
(Di Meco et al., 2014) (Figure 1). It has been described that
sleep restriction increases susceptibility to Amyloid beta (Aβ)-
induced memory impairment in mice (Kincheski et al., 2017),
accompanied by increased plasma levels of corticosterone, just
like higher levels of brain pro-inflammatory cytokines [tumor
necrosis factor alfa (TNFα), interleukin 1 beta (IL1-β) and IL-6],
which contributed to memory impairment and synapse damage.
Consequently, sleep alterations have become major risk factors
for the development of sporadic pathologies like AD and need
to be properly managed by drugs that will restore balanced
physiological sleep periods (Kincheski et al., 2017; Hennawy
et al., 2019).
Benzodiazepines (BZDs) and their analogous Z-drugs
are psychotropic drugs commonly used in medical practice
FIGURE 1 | Schematic representation of potential pathways by which insomnia and benzodiazepines could increase AD risk. Insomnia is a CNS stressor, which
induces microglial activation and oxidative stress. Likewise, oxidative stress may be involved in cognitive impairment by decreasing phosphorylation levels of p-CREB
and altering dendritic spines and synapses. Moreover, sleep disturbances prevent clearing toxic metabolites such as β-amyloid. These lead to an increased
production of inflammatory cytokines and the formation of Aβ-plaques. In turn, BZDs activate GABAA receptors, thus interfering excitatory synapses and decreasing
cognitive reserve. Moreover, these drugs have been shown to decrease BDNF as well as increase β-amyloid precursor protein (APP) mRNA levels and tau
phosphorylation. All these mechanisms could increase the risk of cognitive impairment through neuroinflammation, decrease synaptic plasticity and brain insulin
signaling as well as accumulation of Aβ plaques and neurofibrillary tangles.
against anxiety, nervousness, convulsive states, depression,
and psychosis. They also act as skeletal muscle relaxants and
hypnotics for the treatment of short-term acute insomnia
(Dolder et al., 2007). On a molecular level, BZDs and Z-drugs
facilitate the inhibitory activity of the neurotransmitter gamma-
aminobutyric acid (GABA) on its receptor (Duke et al., 2018),
favoring the flow of chlorine ions through the ionotropic channel
bound to the receptor and producing the hyperpolarization
of neuronal membranes (Sigel and Ernst, 2003). The GABAA
receptor is an ionotropic receptor composed of five protein
subunits that mediate different behavioral and pharmacological
responses (Mehdi, 2012; Duke et al., 2018). The α1 subunit of the
GABAA receptor is thought to be responsible for sedative effects,
while the α2 and α3 subunits exert anxiolytic and antidepressant
activities. Finally, the α5 subunit is involved in the control of
cognitive functions such as memory and learning (Rissman et al.,
2007; Savić et al., 2010).
From a pharmacokinetic point of view, BZDs and related
drugs are divided into three groups according to their half-life.
It can either be long (over 24 h), intermediate (between 6 and
24 h), or short (<6 h). Usually, short and intermediate-acting
BZDs are prescribed for insomnia, while longer-acting BZDs
are reserved for anxiety, but their effects can vary with age and
liver metabolic capacity. Old age is associated with a decrease of
oxidative metabolism, causing an extension on drug half-life due
to changes in pharmacokinetics and pharmacodynamics (Taipale
et al., 2015; Hessmann et al., 2018). In fact, the prolonged use
of these drugs (over 2 months) in advanced age has shown to
produce serious side effects, causing tolerance and dependence,
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increased risk of falls and fractures as well as an impairment of
cognitive processes (Pharmd et al., 2003; Obradovi et al., 2005;
Stewart, 2005; Rissman et al., 2007; Savić et al., 2010; Rosenberg
et al., 2012; Makaron et al., 2013; Biétry et al., 2017; Nørgaard
et al., 2017; Duke et al., 2018; Picton and Pharm, 2018; Underlien
et al., 2018; Scott and Aricescu, 2019).
The effects of BZDs and other hypnotic drugs on cognition
in elderly patients are intensive areas of research nowadays
(Carlisle, 2017). In a recent study, Kurlawala et al. reported a
case of a 76-year-old male who presented onset of short-term
memory loss after a 3 year treatment with a BZD (Kurlawala
et al., 2018). Magnetic resonance imaging studies revealed that
cognitive loss could be a result of atrophy in the hippocampus
and cortex (Barker et al., 2004; Hessmann et al., 2018; Kurlawala
et al., 2018; Picton and Pharm, 2018). Studies performed by
the groups of Glass et al. and Kripke et al. reported that the
adverse effects of hypnotics outweigh the benefit they achieve
in the population older than 60 years, going so far as to
increase mortality risk in some patients (Glass et al., 2005; Kripke
et al., 2012; Hammond and Esclapez, 2015). Consequently, these
results have led the National Institutes of Health and the Beers
Criteria of the American Geriatric Society to list molecules,
such as eszopiclone, zolpidem, and zaleplon, as “potentially
inappropriate medications” (Consensus and Statements, 2014;
Investigations, 2015; Taipale et al., 2015; Wennberg et al., 2018).
It was determined that BZDs should be avoided or should only
be prescribed for short and specific situations (Letter, 2019;
Walsh and Roth). However, BZDs and Z-drugs are still widely
inappropriately prescribed in sleepless patients (Gunja, 2013;
Pariente et al., 2016; Nørgaard et al., 2017; Richardson et al.,
2018).
Luckily, alternatives to BDZs exist to treat situations of
sleep deprivation. Sateia et al. published a clinical practice
guideline for the treatment of insomnia in the Journal of Clinical
Sleep Medicine (Sateia et al., 2017a,b). In their manuscript,
the authors suggest ramelteon for sleep-onset insomnia. This
drug selectively binds to the melatonin receptors, avoiding
dependence and other important side effects associated with
BZD long-term treatment. In the same paper, the authors also
recommend Z-drugs or BZD hypnotics for sleep maintenance in
insomnia (Sateia et al., 2017a). In 2018, the U.S. Food and Drug
Administration (FDA) approved several non-BZD compounds
for the treatment of insomnia (Richardson et al., 2018). These
include antidepressants with anxiolytic or sedative action, such
as escitalopram, doxepin, trimipramine, and amitriptyline as
well as heterocyclic drugs like trazodone and mirtazapine
(Gunja, 2013; Richardson et al., 2018).
The objective of this article was to review and discuss
published material on the risk of BZD and Z-drug use and their
role in the appearance of cognitive loss in cases of AD.
THE POTENTIAL MOLECULAR
MECHANISMS INVOLVED IN
BENZODIAZEPINES AND RELATED DRUG
INDUCED COGNITIVE IMPAIRMENT
Although the molecular mechanisms by which BZDs and
psychotropic drugs could induce cognitive impairment are
uncertain, several hypotheses have been suggested (Gage et al.,
2015). These mechanisms are summarized in Figure 1.
One hypothesis states that elderly long-term consumers of
BZDs show limited cognitive reserve capacity. This concept
refers to the ability to tolerate age-related and disease-related
changes in the brain due to the existence of strong and
redundant synaptic connections in the brain. This mechanism
would allow resisting longer neurodegenerative pathologies
without developing clear cognitive clinical symptoms or
memory loss (Stern, 2012). Since BZDs and Z-drugs are positive
GABAA receptor modulators, they decrease brain activation
and reduce synaptic plasticity, affecting the patient’s ability to
create a new memory. Thus, BZDs interfere with the function
of excitatory synapses, which is required for memory. In
addition, the loss of social networks in aging people could act
as an additional factor that may also affect cognitive function.
Likewise, BZD treatment for sleep disturbances in aging
could limit the capacity to create social communication
networks and precipitate the development of dementia
(Wan et al., 2004; Pariente et al., 2016; Mohamad et al., 2019).
The composition of GABAA receptors could also be involved
in cognitive alterations related to hypnotic drugs. It has been
reported that the binding of BZDs to the α5GABAA subunit,
which is almost exclusively found in the hippocampus and deep
layers of the cortex, impairs memory for contextual information
in monkeys (Wan et al., 2004; Mohamad et al., 2019). Of
note, Zolpidem did not impair the performance of a task based
on visual cues which could be explained by its affinity for
the α1GABAA, instead of α5GABAA (Mohamad et al., 2019).
Moreover, it has been reported that the memory-impairing
effects of BZDs are not blocked by the α1GABAA-selective BZD
antagonist β-carboline-3-carboxylate-3-butyl-ester, whereas the
α5GABAA antagonist XLi-093 blocked the effects of triazolam
but not zolpidem (Caraiscos et al., 2004; Mohamad et al., 2019).
These findings suggest a specific role of α5GABAA receptor in
BZD-related cognitive impairment. Furthermore, recent reports
suggest that the modulation of extrasynaptic tonic inhibition of
α5GABAA in the CA1 hippocampus and cerebral cortex could
improve and regulate memory processes in the hippocampus.
Therefore, negative modulation of α5GABAA could be a suitable
target for the development of potential therapies against cognitive
dysfunction in neurological diseases (Caraiscos et al., 2004).
Contrarily, Joksimović et al. demonstrated that α1GABAA
subunit receptor activation may affect the spatial learning
performance in rodents (Joksimović et al., 2013). They also
reported that α1GABAA subunit is involved in anterograde
amnesia, sedation, motor incapacitation, and anticonvulsant
BZD effects.
On another front, the “GABAergic deafferentation hypothesis
of brain aging” introduced byMarczynski is based on the fact that
administration of diazepam to rats causes a diminution of glucose
utilization in the brain (Marczynski, 1995, 1998). Since a decrease
in cellular adenosine triphosphate (ATP) levels is a feature of
the aging process and AD, it would be logical to consider a
potential metabolic influence of BZDs–GABA receptor complex
in the brain, predisposing to AD in aging (Marczynski, 1995).
Regarding this, the administration of flumazemil, an antagonist
of BZDs, increases glucose utilization in rodents (Marczynski,
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1998). Thus, a potential mechanism explaining the deleterious
effects of BZDs on cognitive processes could be the depolarization
and the depressive action of BZD agonists leading to brain
energy metabolism deficit. In addition, BZD agonists may
inhibit the effects of paracrine-autocrine neurotrophin family.
Indeed, it is well-known that nerve growth factor (NGF)-related
proteins participate in the regulation of survival, growth, and
maintenance of neurons. In this sense, Zhao et al. reported
that mice under long-term diazepam administration showed
behavior alterations and reduced hippocampal synaptophysin
and brain-derived neurotrophic factor (BDNF) levels (Zhao
et al., 2012). This is a matter of importance since BDNF
influences the functional aspects of synaptic transmission by
(i) enhancing the number of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors in the postsynaptic
membrane, (ii) enhancing Long term potentiation (LTP), and
(iii) reducing GABAA receptor expression and decreasing
inhibitory GABA-ergic neuro-transmission in the hippocampus
(Jovanovic, 2004). Through this mechanism, BZDs could inhibit
the axonal transport in both directions, increase the formation of
neurofibrillary tangles, and also induce the βAPP-mRNA gene
expression, thus increasing the risk of AD. Furthermore, the
glutamate levels could also be affected by destabilizing neuronal
Ca2+ homeostasis, and neurons could be more sensitized to the
effects of glutamate (Jovanovic, 2004).
Recently, an interesting study of Whittington and
collaborators reported that midazolam increased tau
phosphorylation in C57BL/6 mice (Whittington et al., 2019).
Consequently, the authors suggested that the effects of the
most frequently used BZDs on tau phosphorylation should be
evaluated in deep since they could be strongly involved in the
increase of AD risk. Indeed, pathogenic forms of tau, including
soluble tau oligomers, can promote neuronal dysfunction and
cognitive loss by several mechanisms at the early stages of
disease (Forner et al., 2017; Tracy and Gan, 2018). Likewise,
Marciniak and collaborators reported that tau protein could be
involved in the regulation of brain insulin signaling, which plays
a fundamental role in the cognitive process (Marciniak et al.,
2017). They demonstrated that the alteration of insulin signaling
in preclinical models of AD could occur through alterations
of tau.
It is also well-known that apolipoprotein E (APOE) 4 allele
is a risk factor of AD (Stonnington et al., 2009). The presence
of this allele is associated with an increased Aβ accumulation
as well as with an increase in cognitive decline and disease
development when compared to other APOE allelic variants.
In this respect, Pomara and collaborators reported an increased
sensitivity to the cognitive adverse effects of acute doses of
lorazepam in elderly carriers of the APOE4 allele (Pomara
et al., 2011). Thus, it seems that APOE4 could also be a risk
for psychotropic drug-mediated cognitive decline. Likewise, the
same group suggested that subjects who carry the very long
Translocase of Outer Mitochondrial Membrane 40 Homolog
(TOMM40) Poly-T Length and do not possess the ǫ4 allele
might also be at increased risk for BZD-related cognitive loss.
Therefore, the influence of APO E genotype on hypnotics as risk
factors for AD seems relevant, and APOE4 genotyping could be
useful in guiding physicians about avoiding BZD prescription in
at risk patients. Finally, Stonnington and collaborators reported
that acute 2mg dose of lorazepam given to middle aged (50–65
years) cognitive normal adults caused higher decline in verbal
episodic memory and visuospatial memory/executive function in
ε4 carriers compared to non-carriers (Stonnington et al., 2009).
However, Aβ might also have indirect effects on the
inhibitory GABAergic transmission as a result of the dynamic
GABAergic balance modulation of the other two excitatory
systems (cholinergic and glutamatergic neurotransmission).
Interestingly, it has recently been suggested that the imbalance
between excitatory and inhibitory systems underlies the synaptic
dysfunction caused by Aβ (Rissman et al., 2007).
CLINICAL STUDIES
Between November 2018 and February 2019, we performed a
literature review on clinical studies linked to the research topic
in three acknowledged databases: Web of Science, Scopus, and
PubMed. The collocated keywords were as follows: Alzheimer’s
disease AND benzodiazepines, Benzodiazepines AND cognitive
impairment, Benzodiazepines AND cognitive decline, hypnotics
AND cognitive decline, Z-drugs AND cognitive impairment,
hypnotics AND Alzheimer’s disease. The keywords were
combined and integrated in the database and journal searches.
The terms used were searched using AND to combine the
keywords listed and using OR to remove search duplication
where possible. References of retrieved articles that the authors’
searches may have missed or could have been ignored were
also assessed.
All these studies were fully investigated and considered under
the following inclusion criteria:
• All articles had to be published studies conducted on human
subjects up to February 2019.
• All articles had to be written in English.
• The primary outcome had to be focused on cognitive decline
and Alzheimer’s disease.
Case–Control Studies
Data from studies reviewed in this section can be found
in Table 1.
In a nested case–control study, Lagnaoui et al. concluded
that there was a small increased risk of dementia after the
administration of GABAA activators (Lagnaoui et al., 2002).
Notwithstanding, the authors acknowledged that the effect of
exposure to other non-evaluated drugs with possible Central
Nervous System (CNS) effects, such as antipsychotics, could
have biased the results. In another study, the same group
evaluated the prevalence of BZD use in AD patients for 3
months, raising awareness about the use of BZDs in elderly AD
patients (Lagnaoui et al., 2002). The same authors conducted
a case–control study with data from a large representative
cohort of Canadian older women in order to examine the
association between BZDs and AD. They found a non-significant
tendency toward an association between former use of BZDs
and increased risk of cognitive decline. Perhaps the low number










































TABLE 1 | Overview of selected case–control studies exploring the effect of BZDs and Z-drugs on the delay of cognitive decline in the elderly and Alzheimer’s disease patients.
References Objective Intervention Number of subjects Main outcome measures Findings
Lagnaoui et al.
(2002)
To investigate link between BZD and dementia
in a large representative cohort of French
community dwelling population. Data from
PAQUID
(Personnes Agées Quid) Research Program in
Bordeaux.
1989–1997 150 cases and 3,519 controls.
Age ≥ 65. Data from the UK-based
Clinical Practice Research Datalink
Cognitive impairment was evaluated using the Mini-
Mental Status Evaluation (MMSE) and CT scanner.
Diagnosis was based on Diagnostic and Statistical
Manual of Mental Disorders (DSM-III-R) and
NINCDS-ADRDA
BZD consumption constitutes
a risk factor for dementia in the
elderly.
Wu et al. (2009) To explore the association between long-term
BZD use and the risk of dementia. Nested
case–control study (Taiwan)
1997–2004 4,626 control subjects, and 779
dementia patients treated with
hypnotics. Age ≥ 45.
Cumulative dose DDD of sedative-hypnotics and




Wu et al. (2011) To explore if BZDs discontinuation affects the
risk of dementia. Nested case–control study
(Taiwan)
1997–2007 8,434 patients with dementia and
16.706 control subjects. Age ≥45.
BZD discontinuation. The risk of AD increases with




To evaluate the association between use of
BZDs and dementia.
1987–1989 1,063 community dwelling people.
Age ≥ 65.
Dementia evaluated based on the Diagnostic and
Statistical Manual of Mental Disorders, third edition,
revised (DSM-III-R).
The use of BDZs was




To evaluate the association between former
BZD use and the risk of AD and to investigate
the potential dose–effect relation (Canada)
2000–2009 1,796 AD patients and 7.184
controls. Age >66.
First diagnosis (index date) of AD (ICD-9
(international classification of disease, ninth revision)
No dose-effect relation
between BZDs and increased
risk of AD was found in older
people treated previously for
more than 3 months.
Imfeld et al. (2015) To assess the association of BZD use with risk
of dementia.
1998–2013 16,823 subjects with AD and 9,636
subjects with vascular dementia and
each being randomly matched (age,
sex, general practice and duration of
follow-up) with one control. Age ≥ 65.
The time of study with these BZDs
was 2 years from the diagnostic of AD
and 3 years from vascular dementia
An algorithm based on recordings of specific
dementia tests [e.g., Mini-Mental State Examination
(MMSE), Clock Drawing Test (CDT), or Abbreviated
Mental Test (7-Min Screen)], referrals to specialists,
brain imaging [computed tomography (CT),
magnetic resonance imaging (MRI), or single photon
emission computed tomography (SPECT)]
symptoms (memory impairment, aphasia, apraxia, or
agnosia) supportive of a diagnosis of a specific
dementia subtype.
Long-term BZDs use is not
associated with an increased
risk of AD or vascular
dementia.
Gomm et al. (2016) To explore the association between BDZ and
Z-drug consumption and dementia in a large
German population over 60 years old in German
public health insurance data Allgemeine
Ortskrankenkassen (AOK), which covers about
50% of the population at least 80 years old
2004–2011
follow-up.
21,145 cases (any dementia) and
84,580 controls, over 60 years of age.
Cognitive tests. Regular use of BDZs and
Z-drugs in the elderly induces




The authors evaluated the effect of BZDs and
Z-drugs administered 2 years before and three
years after the diagnosis of AD. MEDALZ
cohort in Finland.
2005–2011 51,981 patients with AD and 159.974
controls.
AD diagnoses based on the National Institute of
Neurologic and Communicative Disorders and
Stroke and the Alzheimer’s disease and Related
Disorders Association as well as the Diagnostic and
Statistical Manual, Fourth Edition, criteria.
BZD use is higher in AD
patients. BDZs could decrease




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of cases (n = 73) and controls (n = 437) prevented reaching
statistical significance.
Wu et al. conducted two case–control studies in Taiwan using
the National Health Insurance Research Database (NHIRD) with
data of people aged ≥45 from 1997 to 2004 (Wu et al., 2009).
The main conclusions of the study were that long-term use of
BZDs or similar drugs might be associated with increased risk for
dementia and cognitive alterations in prevalent and chronic users
over a maximum follow-up of 8 years. The authors also suggested
that risk of dementia was associated with higher cumulative
dosage and longer duration of BZD exposure (Wu et al., 2009).
In the second study, the same group stated that this association
was reversible since BZD discontinuation could decrease the risk
of dementia (Wu et al., 2011).
In 2012, Billioti de Gage et al. performed a study in a
French population. The main conclusion was that the new use
of BZDs was associated with an about 50% increase in the risk
of AD (Billioti de Gage et al., 2012). In 2014, the same group
assessed the effects of exposure to BZDs among 10 up to 5
years before the diagnosis of AD, considering both the doses
and the reason for prescription (anxiety, depression, insomnia)
in a population of aged individuals of Quebec (Canada) (Billioti
de Gage et al., 2014). They concluded that the chronic use of
BZDs was associated with a higher risk of AD when daily doses
ranged between 91 and 180 mg/kg (cumulative dose expressed
as prescribed daily, during 3–6 months), and increased further
with doses higher than 180 mg/kg (during more than 6 months
of exposure).
Gomm et al. reported that the risk of dementia increased by
21% in patients receiving regular hypnotic drug prescriptions
when compared to non-users (odds ratio [OR] 1.21, 95%
confidence interval [CI] 1.13–1.29; p < 0.001) (Gomm et al.,
2016). The authors also reported the existence of a period
of about 3 years from the first prescription of the BZDs to
the diagnosis of dementia. This study did not create specific
selection methods for those individuals with higher potential
risk of AD, such as those with APOE4 allele or low educational
level. Likewise, the study only focused on the analysis of regular
hypnotic users.
Saarelainen et al. conducted a study in a Finnish cohort
of 70,718 subjects diagnosed with AD between 2005 and 2011
in order to investigate the effects of BZDs and Z-drugs in a
population of AD patients compared with matched controls
(Saarelainen et al., 2016). The authors concluded that these
psychotropic drugs could inhibit the beneficial effects of the
drugs used in the treatment of AD, either anticholinesterases
or memantine. Furthermore, AD patients treated with BZDs
showed a risk of mortality up to 41% higher than those who did
not use such drugs. Z-drugs did not increase the risk of death,
but authors suggested that they could not be considered safer in
persons with dementia (Saarelainen et al., 2018).
Another study was performed in a wide population of Finland
for 6 years (Tapiainen et al., 2018). Currently, this is the
largest study assessing the effect of BZDs and Z-drugs on AD
risk. Moreover, the authors concluded that BZDs and Z-drugs
modestly increased AD risk since the Off Ratios (OR) after
adjusting for another concomitant psychotropic medication was
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TABLE 2 | Cohort studies.
References Objective Intervention Number of subjects Main outcome
measures
Findings
Lopez et al. (1999) To examine the association of
psychotropic medication use
with cognitive, functional, and
AD
1983–1988 179 patients with
Alzheimer’s disease
age 82.2 mean 6.6
Cognitive impairment
was evaluated using the
Mini-Mental Status
Evaluation (MMSE)
BZDs increase the risk of AD
Ellul et al. (2007) To examine the effects of
several drugs on the
progression of disease in
patients with Alzheimer’s
disease.
Not reported 257 patients with
Alzheimer’s disease






Antipsychotics and BZDs were
associated with a greater
cognitive decline in patients
treated with these drugs.
Rosenberg et al.
(2012)




represents years of drug use
divided by years of observation




incident AD cases from the
Cache County Dementia
Progression Study








was associated with more




To evaluate the continuity of
BZDs prescriptions in patients
with dementia insured in a
German public sickness fund
(Allgemeine Ortskrankenkasse
AOK, 2018) in Lower Saxony,
Germany
2014–2015 1,298 subjects with
dementia.






The use of long acting BZD
should be avoided in dementia
patients.
Lee et al. (2018) Association between
sedative-hypnotic use and the
risk of AD, in a Korean
population through a
retrospective cohort study from











the ever exposed, who








exposed to over 360 DDD of
sedative-hypnotics showed a
higher risk of dementia when
compared to non-treated
patients
Grande et al. (2019) To investigate the effect of BDZs
on first cognitive alterations in
primary care patients suffering
early cognitive alterations. Data
comes from the
REMIND—REteMilanese
INtegrata per le Demenze—
database.
Not reported 4,249 subjects (mean age
77.0 ± 8.2) enrolled by
353 General Practitioners
(GPs) in the Milan
metropolitan area.)
Evaluation of cognitive
function by ad hoc
trained GPs, using the
Mini Mental State
Examination (MMSE).
BZD use is not associated
with an increased risk of poorer
cognitive
performance in primary care
patients with first cognitive
complaints.
1.06 (95% CI 1.04–1.08). They did not find significant differences
between BZD subcategories (long or short action).
Controversially, there are some studies questioning the notion
that BZDs/Z-drugs increase the risk of cognitive loss. For
instance, in a study performed by Infeld et al., the results
showed that long term use of BZDs did not increase the risk
of AD (Imfeld et al., 2015). Adjusted odds ratios (aORs) were
calculated with 95% confidence intervals (CIs) of developing
AD or VaD in relation to previous BZD use, stratified by
duration and benzodiazepine type. The OR of developing AD
for those who started BZDs 1 year before AD diagnosis was
2.20 (1.91–2.53) and fell to the null for those who started
between 2 and 3 years before [aOR 0.99 (0.84–1.17)] (Imfeld
et al., 2015). In the same line, Biétry et al. evaluated the
risk of AD after a period of 2 years of BZD and related
drug treatment before AD diagnosis (Biétry et al., 2017). The
results of the study indicated that the risk of developing AD
was not associated with BZDs or Z-drugs. Likewise, the half-
life of BZDs was not linked with AD risk (Biétry et al.,
2017).
Cohort Studies
Data from studies reviewed in this section can be found
in Table 2.
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Several prospective and retrospective cohort studies which
have assessed the association of BZDs/Z-drugs and related drugs
on cognitive function reported controversial results.
For example, the study of Lopez et al. concluded that the use
of BZDs in AD patients should be done with great caution and
its use would not be adequate due to the risks of falls (Lopez
et al., 1999). Also, in the treatment of insomnia, they suggested
the use of other medications such as antihistaminic drugs. Also,
Ellul et al. suggested that the prescription of antipsychotics and
BZDs can accelerate cognitive decline in patients with AD (Ellul
et al., 2007). In the prospective long-term “Caerphilly study,”
results also evidenced the association between the use of BZDs
and the increased risk of developing both vascular and non-
vascular dementia (Gallacher et al., 2012). The authors studied
a representative sample of men with a follow-up rate over
22 years. They reported a significant higher risk for dementia
with the use of BZDs. Moreover, Rosenberg et al. suggested
that antipsychotics and BZDs showed an increase in cognitive
loss associated with a high Persistency Index (Rosenberg et al.,
2012). Lee et al. evaluated the risk of AD after the use of
sedative-hypnotic antidepressants and antipsychotic drugs (Lee
et al., 2018). Interestingly, the risk of AD was higher in patients
receiving a defined daily dose over 30 defined daily dose (DDD).
Likewise, in this study, different groups of BZDs were evaluated,
and intermediate BZDs were associated with the highest risk
of dementia. This study concluded that the risk of AD was
associated with BZDs and sedative-hypnotic drugs, and that this
association was dose-dependent (Lee et al., 2018). In another
study performed in Taiwan, Chen et al. used data from the
NHIRD, which covered 23 million registered patients from 1995
to 2010, accounting for 99% of the population (Chen et al., 2012).
The authors clearly indicated the hypnotic drugs used which
were classified into two groups: BZDs and Z-drugs. The results
suggested that both hypnotics should be considered risk factors
for dementia in patients with long-term insomnia. Likewise, an
association between higher prescribed dosages of BZDs and Z-
drugs and risks of dementia was found, which is in agreement
with previous studies (Tapiainen et al., 2018).
It has been proposed that older people with anxiety may have
a higher risk of AD development and involved an increase of
Aβ levels in adults with MCI and AD (Pietrzak et al., 2015).
Thus, Burke et al. investigated the role of anxiolytic drugs
in the risk of AD. Likewise, they evaluated the association of
APOE ε4, currently the most important risk factor in LOAD
(Burke et al., 2018). One important finding of the study was
that ε4 carriers had a statistically higher significant risk of AD
development; however, this effect was moderated by the use of
anxiolytics. Anxiolytics, alprazolam, lorazepam, paroxetine, or
venlafaxine, specifically, may improve the association of anxiety
on MCI and AD development. However, in the same study
the authors reported that clonazepam conferred a statistically
significant increased risk of MCI development among users of ε4
with anxiety, suggesting that there is a molecular mechanism on
cognition that is altered by clonazepam.
Divergently, the prospective population-based cohort study
published by Gray et al. investigated the risk of dementia
associated with cumulative dosage of BZDs after an average
follow-up of 7 years (Gray et al., 2016). They reported
a small increased risk of dementia in people with low
or moderate BZD treatment. However, the study concluded
that BZDs do not increase the risk of AD (Gray et al.,
2016). Furthermore, another team examined patients with
recently diagnosed mild AD which were treated with anti-
dementia medications such as acetylcholinesterase inhibitors
(donepezil, galantamine, rivastigmine) and memantine. The
authors reported an association between AD and an increased
use of psychotropic drugs (Törmälehto et al., 2017). However,
the administration of psychotropic medications was not related
to alterations in cognitive performance (Törmälehto et al., 2017).
Finally, Grande and collaborators showed that patients treated
with short- and long-acting BZDs presented adjusted MMSE
mean scores of 25.4; 95%CI 25.1–25.7, while non-treated patients
had 25.9; 95% CI 25.3–26.4 (short acting BZDs); 25.3; 95% CI
25.2–25.5 (long-acting BZDs); (p = 0.156) (Grande et al., 2019).
Therefore, the authors stated that the use of BZDs was not
associated with an increase in cognitive loss in patients suffering
initial cognitive alterations.
Longitudinal Studies
Data from studies reviewed in this section can be found
in Table 3.
In a study performed in a young adult population, Boeuf-
Cazou et al. concluded that, although long-term exposure to
BZDs leads to specific impairment in long-term memory only in
women, a longer period of observation is necessary to ascertain if
these alterations are associated with a risk of developing dementia
in old age (Boeuf-Cazou et al., 2011).
Yet, in a large population-based cohort study named “The
Three-City Study,” Shash et al. compared short- vs. long-half-life
BZDs as well as the effects of other psychotropic medications on
dementia on non-institutionalized individuals aged ≥65 starting
in 1999. The authors concluded that users of long half-life
BZDs had a 60% increased risk of developing dementia (Shash
et al., 2016). Also, it was examined whether the chronic use
of BZDs over 4 years was associated with an increased risk of
cognitive decline (Paterniti et al., 2002). The study demonstrated
that prolonged use of BZDs was a significant risk factor for
the cognitive decline in the elderly which was evaluated by the
MMSE, the Trail Making Test, and the Digit Symbol Substitution.
Finally, it had been described that BZDs decrease cognitive
performance, although the effects were small. In addition, they
suggested that higher BZD treatment duration and cumulative
doses were responsible for the negative effects on cognition in
elderly patients (Bierman et al., 2007).
Cross-Sectional Studies
Data from studies reviewed in this section can be found
in Table 4.
Mura et al. conducted a cross-sectional and longitudinal
study to evaluate the effects of chronic BZD use on cognitive
decline in people over 65 years old in France (Mura et al.,
2013). A total of 5,195 persons were included in the study,
969 of which were chronic users of BZDZs. The results
showed that chronic BZD use was associated with poorer
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TABLE 3 | Longitudinal studies.
References Objective Intervention Number of subjects Main outcome measures Findings
Bierman et al.
(2007)
To evaluate the effects of BZD
use on cognitive function in the










means of the Mini-mental State;
Episodic memory measured with
a Auditory Verbal Learning Test;
Fluid intelligence
measured by means of two
sub-sets of 12 items (A and B)
from Raven’s Colored
Progressive Matrices; Information
processing speed measured by
means of an adjusted version of
the Coding task.
The duration of treatment and
cumulative exposure to BZD
use had a negative effect on
the cognitive function of elderly




To investigate the impact of
long-term BZD consumption on
cognitive function Population
from the VISAT study (Aging,




1,660 men and 1,577
women aged 32, 42, 52,
and 62 years, classified




Cognitive function was assessed
using five cognitive tests
(immediate free recall test,
delayed free recall test,
recognition test, Digit Symbol
Substitution Subtest and visual
search speed test).
Long-term use of BDZs leads
to specific impairment in
long-term memory in women.
TABLE 4 | Cross-sectional studies.





To investigate the prevalence of
BZD and related-drug
consumption, especially those
of long-term, and its associated
factors among community
dwelling individuals with and
without AD.
2002–2006 The number of persons included
in the study was 24,966 for
individuals with AD and 24,985
for individuals without AD. The
research was based on data
from the MEDALZ-2005
(Medication use and Alzheimer’s
disease) cohort, which includes
all community-dwelling
individuals, diagnosed with AD in
Finland at the end of 2005 and
matched individuals without AD.




The long-term use of BDZs
may impair cognition and may




To evaluate the continuity
of BZD prescriptions among
dementia patients in Lower
Saxony, Germany.




The use of long acting BZD
should be avoided by
dementia patients.
cognitive performance, but not with accelerated cognitive
decline with age. However, the authors stated that BZDs
could deteriorate cognitive performance, increase the depletion
of cognitive reserves and precipitate the onset of dementia
(Mura et al., 2013). Later, another team aimed to evaluate
the prevalence of BZD and Z-drug use in a population of
Finland (Taipale et al., 2015). The authors concluded that
approximately half of the people with AD used BZDs and Z-
drugs during the 4 years of follow-up, and that AD patients
used more BZDs in the long term that those without AD.
In another study, the same group investigated the risk of
any stroke (ischemic or hemorrhagic) associated with BZDs
and Z-drugs in patients with AD taken from the MEDALZ-
2005 population. They found an increase of 20% in the risk
of ischemic stroke in AD patients using BZDs and Z-drugs.
However, the risk of hemorrhagic stroke was not increased
(Tolppanen et al., 2017).
Contrarily, Zhang et al. who collected data from the National
Institute on Aging (NIA) ADCs, reported no association between
BZDs and cognitive decline (Zhang et al., 2016).
Meta-Analyses
Zhong et al. investigated the association of long-term BZD
use and dementia in a meta-analysis including five studies,
which involved 45,391 participants and 1,891 dementia cases. In
addition, the authors evaluated the potential risk of dementia
associated with an increase of BZD dose by 22% (risk ratio 1:22,
95% CI 1.18–1.25). They concluded that long-term BZD users
had an increased risk of dementia compared with non-users
(Zhong et al., 2015).
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In turn, He et al. pooled 10 studies to assess the association
between BZDs and risk of dementia. PubMed and Embase
databases were systematically searched for relevant publications
up to September 2017. The literature search focused on
observational studies that analyzed the relationship between the
long-term use of BDZs and the risk of dementia. Their main
findings pointed to a significantly increased risk of dementia in
the elderly population using BZDs. This effect was associated
with the use of BZDs with a longer half-life and with a longer
treatment duration (He et al., 2019).
Finally, a meta-analysis of 12 prospective and retrospective
cohort studies and case–control studies about the risk of BZDs
and AD was reported. The team concluded that the use of
BZDs—mainly those of long-action—and Z-drugs was associated
with the development of dementia. However, the study showed
some limitations since it did not differentiate between BZDs
effects on AD and vascular dementias, neither between long- and
short-acting BZDs (Lucchetta, 2018).
DISCUSSION
In the present review, we discussed the evidence pointing to
BZDs as risks factors for cognitive decline in aging and AD
(Paterniti et al., 2002; Zhang et al., 2016; Picton and Pharm,
2018).
Sleep disorders increase with age, altering clearance of toxic
and waste products from the brain, including Aβ (Clinton
et al., 2011). It has been reported that sleep disturbances
could contribute to neurodegeneration and AD by altering
physiological metabolic functions, increasing oxidative stress,
and the accumulation of Aβ as well as due to the appearance
of neuroinflammatory responses (Phan and Malkani, 2019)
(Figure 1). In addition, insomnia is also associated with
hypertension, diabetes, and a higher obesity risk; all of them
contributing to AD (Clarke et al., 2018; Frozza et al., 2018).
Bearing this in mind and considering the increase in insomnia
diagnostics, especially in the elderly, this situation has led to
higher consumption of hypnotic drugs in the adult population
to improve sleep quality. Notwithstanding, and seeing the
possible consequences derived from their intake, there needs
to be a significant increase in awareness about their risks.
In fact, there have been some studies reporting that the
consumption of BZDs favors the appearance of cognitive
affectations and increases the number of deaths in patients
with AD (Imfeld et al., 2015; Saarelainen et al., 2017; Grande
et al., 2019). Yet, as we have already assessed, there is
controversy, and other researchers defend that BDZs have
no such detrimental effects (Picton and Pharm, 2018). Thus,
even though BZDs improve various measures of insomnia
in the aged population, their clinical value is debatable,
and melatonin agonists could be a much safer choice when
trying to manage sleep disorders (Investigations, 2015). For
the treatment of anxiety in the elderly, the administration
of other medications such as serotonin uptake inhibitors
(sertraline) or other compounds could be more adequate
(Consensus and Statements, 2014; Investigations, 2015).
In the end, the mechanisms by which BZDs and Z-drugs could
increase the risk of cognitive loss and AD remain to be clarified;
here we have discussed some specific hypotheses. Thanks to
molecular biology, the α1 subunit of the GABA has been shown
to play an important role in BZD-mediated cognitive loss.
Hence, it has been reported that higher activity at the α1GABAA
receptors induced by positive allosteric modulation at the BZD
site is responsible for spatial learning and memory incapacitation
in preclinical models. Besides, activation of the α5 subunit, which
is mainly expressed in the hippocampus, could in part explain
the memory deficit states induced by BZDs. Therefore, α5GABA-
targeting compounds could improve cognition, thus having
therapeutic potential in AD and other dementias (Adrienn et al.,
2017). It is conceivable that BZDs influence cognition and
probably increase the risk of AD acting through hippocampal
α5GABAA, while Z-drugs (α5GABAA-independent) confer a
lower risk. In addition, the neuroinflammatory process is per
se a risk factor for AD. The brain microglia play a prominent
role in neuroinflammation, and it is associated with the secretion
of pro-inflammatory cytokines. Likewise, α5GABAA receptor
activity is enhanced by the inflammatory process, a fact that
is probably critical in inflammation-induced memory deficits
(Marczynski, 1998). Moreover, BZDs and other drugs may
increase cognitive loss and AD risk through the phosphorylation
of tau protein, which can also inhibit the signaling of the
brain insulin receptor (Jovanovic, 2004; Whittington et al.,
2019).
In spite of these described effects, it could be hypothesized
that BZDs may indirectly exert a protective effect against
the development of AD by improving sleep (through their
clinical effects on sleep latency, number of awakenings,
and duration and quality of sleep) (Guzmán et al., 2018).
This paradigm states that the enhancement of GABAA
receptor activity by BZDs could inhibit glutamatergic
neurotransmission, thereby protecting against the excitotoxic
effects of glutamate on the pathogenesis of AD (Fastbom et
al., 1998). Moreover, it is noteworthy that some clinical trials
reported no association between BZDs and risk of cognitive loss
and AD.
In conclusion, we do not have enough data to ensure a
causal relation between psychotropic drugs and cognitive
loss. However, a therapeutic strategy based on BZDs and
Z-drugs in elderly people should be extensively evaluated
and monitored (Monzani et al., 2015; Yi et al., 2018).
After reviewing the available data, a controversial question
remains: is it safe to prescribe BZDs and Z-drugs to improve
sleep in older patients, despite the potential cognitive loss
risk? We strongly believe that there are enough data
supporting an extremely cautious attitude with Z-drugs
and the avoidance of BZD prescription in elderly people
with AD.
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